Table 1.
Selective Estrogen receptor modulators (SERMs) and selective Estrogen receptor degraders (SERDs)
| Drug | Type | Phase | References |
|---|---|---|---|
| Tamoxifen | SERM | approved | [189] |
| Raloxifene | SERM | approved | [184] |
| Toremifene | SERM | approved | [185–187] |
| Bazedoxifene | SERM | approved | [188] |
| Fulvestrant | SERD | approved | [189, 190] |
| Elacestrant | SERD | approved | [191] |
| Afimoxifene | SERM | Phase III | [192] |
| TAS-108 | SERM | Phase II | [193] |
| Lasofoxifene | SERM | Phase III | [194] |
| Arzoxifene | SERM | Investigational | [195] |
| Ormeloxifene | SERM | Investigational | [196] |
| Pipendoxifene | SERM | Investigational | [197] |
| Droloxifene | SERM | Investigational | [198] |
| Icaritin | SERM | Investigational | [199] |
| Acolbifene | SERM | Investigational | [200] |
| Enclomiphene | SERM | Investigational | [201] |
| ICI-164,384 | SERD | Phase I | [202] |
| AZD-9496 | SERD | Investigational | [203] |
| GDC-0810 | SERD | Investigational | [204] |
| Camizestrant | SERD | Investigational | [205] |
| Giredestrant | SERD | Investigational | [206] |
| Imlunestrant | SERD | Investigational | [207] |